151 filings
Page 2 of 8
6-K
6oklxh8y75oxt5w73
9 Nov 22
Current report (foreign)
7:03am
6-K
t9lf6 jbnv5mgw
21 Sep 22
Current report (foreign)
4:16pm
6-K
buwp2abigcn1no vf
11 Aug 22
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
7:33am
6-K
n7926cs1jtai5cimsd0
4 Aug 22
Current report (foreign)
7:18am
6-K
yayus
30 Jun 22
Current report (foreign)
4:32pm
6-K
o0dq xd6c
1 Jun 22
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
7:05am
6-K
mpm5z329pxe g9
5 May 22
Current report (foreign)
12:00am
6-K
f2a01o zkwg6oa
13 Apr 22
Current report (foreign)
8:02am
6-K
430k8njza22r
13 Apr 22
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
7:09am
6-K
qf8218m3b
24 Feb 22
Current report (foreign)
7:39am
6-K
dlatd2z11r1ysa
11 Feb 22
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
7:39am
6-K
i7yh95wkvwnc6i8g6
4 Jan 22
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
7:12am
6-K
1wiscc
30 Dec 21
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
7:19am
6-K
ycpwzqx2
16 Dec 21
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A mediated Retinitis Pigmentosa
7:23am
6-K
3l9nby
18 Nov 21
ProQR Announces Highlights from Analyst Event
4:25pm
6-K
ai5 znp9jskkap356
18 Nov 21
Current report (foreign)
11:46am
6-K
y7iivt5huqcucv
4 Nov 21
Current report (foreign)
7:30am
6-K
ecd02s
4 Oct 21
ProQR Appoints Theresa Heggie as Chief Commercial Officer
8:21am
6-K
0b4e2f0eaqq1trq5 yg
9 Sep 21
Current report (foreign)
8:01am
6-K
c41mm7b mn35
8 Sep 21
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
4:10pm